Agios Pharmaceuticals, Inc.
Clinical trials sponsored by Agios Pharmaceuticals, Inc., explained in plain language.
-
New hope for rare blood disorder: experimental drug shows promise in phase 2 trial
Disease control CompletedThis study tested a drug called mitapivat (AG-348) in 52 adults with pyruvate kinase deficiency, a rare genetic condition that causes red blood cells to break down too quickly, leading to anemia. The goal was to see if different doses of the drug are safe and can help control the…
Phase: PHASE2 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 05:34 UTC
-
New hope for rare blood disorder: Long-Term drug study shows promise
Disease control CompletedThis study tested the long-term safety and effectiveness of the drug mitapivat in 90 adults with pyruvate kinase deficiency, a rare genetic blood disorder that causes red blood cells to break down too quickly. Participants had already completed earlier studies of mitapivat and co…
Phase: PHASE3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New drug AG-181 passes first safety check in healthy volunteers
Knowledge-focused CompletedThis early-stage study tested the safety and tolerability of a new drug called AG-181 in 88 healthy adults. Participants received either the drug or a placebo, and researchers monitored side effects and how the drug was processed in the body. The study also looked at whether food…
Phase: PHASE1 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 04, 2026 16:30 UTC